In September 2022, deucravacitinib (Sotyktu), a first-in-class oral, allosteric tyrosine kinase 2 (TYK2) inhibitor for moderate-to-severe plaque psoriasis, was approved by the FDA. Aside from its first-in-class mechanism of action, it is the first approved de novo deuterated drug.
This premium deep dive into deucravacitinib includes:
- the industry context
- the clinical data
- the target rationale
- the mechanism of action
- the drug’s origins
See our overview of all 36 of the novel small molecule and large molecule FDA approvals for 2022 here.
request a trial
Premium members get access to our library of hundreds of in-depth reviews on key molecules, ten new reviews each month, novel drug approval coverage, drug discovery company updates, and more.
Interested in learning more? Submit this form to request a trial.